WO2018143652A1 - 면역 관용성 플라즈마사이토이드 수지상 세포 및 그 제조방법 - Google Patents
면역 관용성 플라즈마사이토이드 수지상 세포 및 그 제조방법 Download PDFInfo
- Publication number
- WO2018143652A1 WO2018143652A1 PCT/KR2018/001299 KR2018001299W WO2018143652A1 WO 2018143652 A1 WO2018143652 A1 WO 2018143652A1 KR 2018001299 W KR2018001299 W KR 2018001299W WO 2018143652 A1 WO2018143652 A1 WO 2018143652A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- dendritic cells
- agonist
- differentiation
- toll
- cells
- Prior art date
Links
- 210000005134 plasmacytoid dendritic cell Anatomy 0.000 title claims abstract description 164
- 230000006058 immune tolerance Effects 0.000 title claims abstract description 30
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 13
- 210000004443 dendritic cell Anatomy 0.000 claims abstract description 139
- 210000004027 cell Anatomy 0.000 claims abstract description 64
- 238000000034 method Methods 0.000 claims abstract description 38
- 239000003814 drug Substances 0.000 claims abstract description 18
- 229940124597 therapeutic agent Drugs 0.000 claims abstract description 15
- 230000004069 differentiation Effects 0.000 claims description 136
- 239000003970 toll like receptor agonist Substances 0.000 claims description 111
- 229940123384 Toll-like receptor (TLR) agonist Drugs 0.000 claims description 85
- 238000011282 treatment Methods 0.000 claims description 65
- 239000000556 agonist Substances 0.000 claims description 43
- 230000000694 effects Effects 0.000 claims description 33
- 210000003289 regulatory T cell Anatomy 0.000 claims description 30
- 230000001939 inductive effect Effects 0.000 claims description 23
- 101000831567 Homo sapiens Toll-like receptor 2 Proteins 0.000 claims description 12
- 102100024333 Toll-like receptor 2 Human genes 0.000 claims description 12
- 101100481579 Mus musculus Tlr11 gene Proteins 0.000 claims description 8
- 101100481580 Mus musculus Tlr12 gene Proteins 0.000 claims description 8
- 102100020715 Fms-related tyrosine kinase 3 ligand protein Human genes 0.000 claims description 7
- 101710162577 Fms-related tyrosine kinase 3 ligand protein Proteins 0.000 claims description 7
- 210000003162 effector t lymphocyte Anatomy 0.000 claims description 7
- 229940044655 toll-like receptor 9 agonist Drugs 0.000 claims description 7
- 229940044616 toll-like receptor 7 agonist Drugs 0.000 claims description 6
- 101000669447 Homo sapiens Toll-like receptor 4 Proteins 0.000 claims description 5
- 102000010168 Myeloid Differentiation Factor 88 Human genes 0.000 claims description 5
- 108010077432 Myeloid Differentiation Factor 88 Proteins 0.000 claims description 5
- 229940124614 TLR 8 agonist Drugs 0.000 claims description 5
- 102100039360 Toll-like receptor 4 Human genes 0.000 claims description 5
- VUDQSRFCCHQIIU-UHFFFAOYSA-N 1-(3,5-dichloro-2,6-dihydroxy-4-methoxyphenyl)hexan-1-one Chemical compound CCCCCC(=O)C1=C(O)C(Cl)=C(OC)C(Cl)=C1O VUDQSRFCCHQIIU-UHFFFAOYSA-N 0.000 claims description 4
- 101000942967 Homo sapiens Leukemia inhibitory factor Proteins 0.000 claims description 4
- 101000763579 Homo sapiens Toll-like receptor 1 Proteins 0.000 claims description 4
- 101000669406 Homo sapiens Toll-like receptor 6 Proteins 0.000 claims description 4
- 102100032352 Leukemia inhibitory factor Human genes 0.000 claims description 4
- 101100481581 Mus musculus Tlr13 gene Proteins 0.000 claims description 4
- 102100027010 Toll-like receptor 1 Human genes 0.000 claims description 4
- 102100039387 Toll-like receptor 6 Human genes 0.000 claims description 4
- DAZSWUUAFHBCGE-KRWDZBQOSA-N n-[(2s)-3-methyl-1-oxo-1-pyrrolidin-1-ylbutan-2-yl]-3-phenylpropanamide Chemical compound N([C@@H](C(C)C)C(=O)N1CCCC1)C(=O)CCC1=CC=CC=C1 DAZSWUUAFHBCGE-KRWDZBQOSA-N 0.000 claims description 4
- 101000669460 Homo sapiens Toll-like receptor 5 Proteins 0.000 claims description 3
- 102100039357 Toll-like receptor 5 Human genes 0.000 claims description 3
- 102000004632 fms-Like Tyrosine Kinase 3 Human genes 0.000 claims description 3
- 108010003374 fms-Like Tyrosine Kinase 3 Proteins 0.000 claims description 3
- 108700014844 flt3 ligand Proteins 0.000 claims description 2
- 230000008569 process Effects 0.000 abstract description 9
- 101100511576 Mycobacterium tuberculosis (strain ATCC 25618 / H37Rv) lprG gene Proteins 0.000 description 51
- 210000001744 T-lymphocyte Anatomy 0.000 description 40
- 102000004127 Cytokines Human genes 0.000 description 29
- 108090000695 Cytokines Proteins 0.000 description 29
- 230000035755 proliferation Effects 0.000 description 25
- VQWNELVFHZRFIB-UHFFFAOYSA-N odn 1826 Chemical compound O=C1NC(=O)C(C)=CN1C(O1)CC(O)C1COP(O)(=O)OC1CC(N2C(NC(=O)C(C)=C2)=O)OC1COP(O)(=O)OC1CC(N2C3=C(C(NC(N)=N3)=O)N=C2)OC1COP(O)(=O)OC1CC(N2C(N=C(N)C=C2)=O)OC1COP(O)(=O)OC1CC(N2C3=NC=NC(N)=C3N=C2)OC1COP(O)(=O)OC1CC(N2C3=C(C(NC(N)=N3)=O)N=C2)OC1COP(O)(=O)OC1CC(N2C(NC(=O)C(C)=C2)=O)OC1COP(O)(=O)OC1CC(N2C(N=C(N)C=C2)=O)OC1COP(O)(=O)OC1CC(N2C(N=C(N)C=C2)=O)OC1COP(O)(=O)OC1CC(N2C(NC(=O)C(C)=C2)=O)OC1COP(O)(=O)OC(C(O1)COP(O)(=O)OC2C(OC(C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=O)OC2C(OC(C2)N2C(N=C(N)C=C2)=O)COP(O)(=O)OC2C(OC(C2)N2C3=NC=NC(N)=C3N=C2)COP(O)(=O)OC2C(OC(C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=O)OC2C(OC(C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)OC2C(OC(C2)N2C3=NC=NC(N)=C3N=C2)COP(O)(=O)OC2C(OC(C2)N2C(N=C(N)C=C2)=O)COP(O)(=O)OC2C(OC(C2)N2C(N=C(N)C=C2)=O)COP(O)(=O)OC2C(OC(C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(O)=O)CC1N1C=C(C)C(=O)NC1=O VQWNELVFHZRFIB-UHFFFAOYSA-N 0.000 description 22
- 102000002689 Toll-like receptor Human genes 0.000 description 15
- 108020000411 Toll-like receptor Proteins 0.000 description 15
- 230000028327 secretion Effects 0.000 description 14
- 239000000427 antigen Substances 0.000 description 13
- 239000000203 mixture Substances 0.000 description 12
- 108091007433 antigens Proteins 0.000 description 11
- 102000036639 antigens Human genes 0.000 description 11
- 230000000052 comparative effect Effects 0.000 description 11
- 230000028993 immune response Effects 0.000 description 11
- 210000001185 bone marrow Anatomy 0.000 description 10
- 230000006698 induction Effects 0.000 description 10
- 238000002659 cell therapy Methods 0.000 description 9
- 108020004201 indoleamine 2,3-dioxygenase Proteins 0.000 description 9
- 102000006639 indoleamine 2,3-dioxygenase Human genes 0.000 description 9
- 238000000926 separation method Methods 0.000 description 9
- 102100022718 Atypical chemokine receptor 2 Human genes 0.000 description 8
- 101000678892 Homo sapiens Atypical chemokine receptor 2 Proteins 0.000 description 8
- 101000716070 Homo sapiens C-C chemokine receptor type 9 Proteins 0.000 description 8
- 238000000684 flow cytometry Methods 0.000 description 8
- 238000011534 incubation Methods 0.000 description 8
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 7
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 7
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 230000004044 response Effects 0.000 description 7
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 7
- 208000023275 Autoimmune disease Diseases 0.000 description 6
- 238000002965 ELISA Methods 0.000 description 6
- 102100026720 Interferon beta Human genes 0.000 description 6
- 108010047761 Interferon-alpha Proteins 0.000 description 6
- 102000006992 Interferon-alpha Human genes 0.000 description 6
- 108090000467 Interferon-beta Proteins 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 6
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 6
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 6
- 238000010586 diagram Methods 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 210000002865 immune cell Anatomy 0.000 description 6
- 239000003446 ligand Substances 0.000 description 6
- 238000007898 magnetic cell sorting Methods 0.000 description 6
- OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 108010074708 B7-H1 Antigen Proteins 0.000 description 5
- 102000008096 B7-H1 Antigen Human genes 0.000 description 5
- 102000008070 Interferon-gamma Human genes 0.000 description 5
- 108010074328 Interferon-gamma Proteins 0.000 description 5
- 102000043131 MHC class II family Human genes 0.000 description 5
- 108091054438 MHC class II family Proteins 0.000 description 5
- 239000012980 RPMI-1640 medium Substances 0.000 description 5
- 230000000735 allogeneic effect Effects 0.000 description 5
- 239000012091 fetal bovine serum Substances 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 230000002757 inflammatory effect Effects 0.000 description 5
- 229960003130 interferon gamma Drugs 0.000 description 5
- 230000000638 stimulation Effects 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 230000003213 activating effect Effects 0.000 description 4
- 208000026935 allergic disease Diseases 0.000 description 4
- 230000003110 anti-inflammatory effect Effects 0.000 description 4
- 238000012790 confirmation Methods 0.000 description 4
- 210000003743 erythrocyte Anatomy 0.000 description 4
- 244000052769 pathogen Species 0.000 description 4
- 230000001717 pathogenic effect Effects 0.000 description 4
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 3
- -1 IL-12p70 Proteins 0.000 description 3
- 102000002227 Interferon Type I Human genes 0.000 description 3
- 108010014726 Interferon Type I Proteins 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 230000030741 antigen processing and presentation Effects 0.000 description 3
- 210000000612 antigen-presenting cell Anatomy 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 208000026278 immune system disease Diseases 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 238000003018 immunoassay Methods 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 230000000977 initiatory effect Effects 0.000 description 3
- 238000011813 knockout mouse model Methods 0.000 description 3
- 239000006210 lotion Substances 0.000 description 3
- 230000035800 maturation Effects 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 238000007799 mixed lymphocyte reaction assay Methods 0.000 description 3
- 210000001616 monocyte Anatomy 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000002062 proliferating effect Effects 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 101150013553 CD40 gene Proteins 0.000 description 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 2
- 101000599852 Homo sapiens Intercellular adhesion molecule 1 Proteins 0.000 description 2
- 101000959820 Homo sapiens Interferon alpha-1/13 Proteins 0.000 description 2
- 102100022297 Integrin alpha-X Human genes 0.000 description 2
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 description 2
- 102100040019 Interferon alpha-1/13 Human genes 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- 229930182816 L-glutamine Natural products 0.000 description 2
- 102000043129 MHC class I family Human genes 0.000 description 2
- 108091054437 MHC class I family Proteins 0.000 description 2
- 101150053046 MYD88 gene Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 102100024134 Myeloid differentiation primary response protein MyD88 Human genes 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 description 2
- 230000005867 T cell response Effects 0.000 description 2
- 108091023040 Transcription factor Proteins 0.000 description 2
- 102000040945 Transcription factor Human genes 0.000 description 2
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 235000019270 ammonium chloride Nutrition 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 244000309466 calf Species 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 239000002537 cosmetic Substances 0.000 description 2
- 230000001086 cytosolic effect Effects 0.000 description 2
- 210000004544 dc2 Anatomy 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 239000003797 essential amino acid Substances 0.000 description 2
- 235000020776 essential amino acid Nutrition 0.000 description 2
- DNJIEGIFACGWOD-UHFFFAOYSA-N ethyl mercaptane Natural products CCS DNJIEGIFACGWOD-UHFFFAOYSA-N 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 238000003306 harvesting Methods 0.000 description 2
- 230000001506 immunosuppresive effect Effects 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- PGHMRUGBZOYCAA-UHFFFAOYSA-N ionomycin Natural products O1C(CC(O)C(C)C(O)C(C)C=CCC(C)CC(C)C(O)=CC(=O)C(C)CC(C)CC(CCC(O)=O)C)CCC1(C)C1OC(C)(C(C)O)CC1 PGHMRUGBZOYCAA-UHFFFAOYSA-N 0.000 description 2
- PGHMRUGBZOYCAA-ADZNBVRBSA-N ionomycin Chemical compound O1[C@H](C[C@H](O)[C@H](C)[C@H](O)[C@H](C)/C=C/C[C@@H](C)C[C@@H](C)C(/O)=C/C(=O)[C@@H](C)C[C@@H](C)C[C@@H](CCC(O)=O)C)CC[C@@]1(C)[C@@H]1O[C@](C)([C@@H](C)O)CC1 PGHMRUGBZOYCAA-ADZNBVRBSA-N 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N p-hydroxybenzoic acid methyl ester Natural products COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 230000008823 permeabilization Effects 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 201000008752 progressive muscular atrophy Diseases 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 229940054269 sodium pyruvate Drugs 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000003614 tolerogenic effect Effects 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- 102100032814 ATP-dependent zinc metalloprotease YME1L1 Human genes 0.000 description 1
- 102100036301 C-C chemokine receptor type 7 Human genes 0.000 description 1
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 229940046168 CpG oligodeoxynucleotide Drugs 0.000 description 1
- 241000450599 DNA viruses Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 101000716065 Homo sapiens C-C chemokine receptor type 7 Proteins 0.000 description 1
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 description 1
- 101001046686 Homo sapiens Integrin alpha-M Proteins 0.000 description 1
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 1
- 101000831496 Homo sapiens Toll-like receptor 3 Proteins 0.000 description 1
- 102100022338 Integrin alpha-M Human genes 0.000 description 1
- 108010009489 Lysosomal-Associated Membrane Protein 3 Proteins 0.000 description 1
- 102100038213 Lysosome-associated membrane glycoprotein 3 Human genes 0.000 description 1
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 1
- 108091036414 Polyinosinic:polycytidylic acid Proteins 0.000 description 1
- 101800000795 Proadrenomedullin N-20 terminal peptide Proteins 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 230000006052 T cell proliferation Effects 0.000 description 1
- 102000008228 Toll-like receptor 2 Human genes 0.000 description 1
- 108010060888 Toll-like receptor 2 Proteins 0.000 description 1
- 102100024324 Toll-like receptor 3 Human genes 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000033289 adaptive immune response Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000005860 defense response to virus Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 239000012645 endogenous antigen Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- BHEPBYXIRTUNPN-UHFFFAOYSA-N hydridophosphorus(.) (triplet) Chemical compound [PH] BHEPBYXIRTUNPN-UHFFFAOYSA-N 0.000 description 1
- 230000000521 hyperimmunizing effect Effects 0.000 description 1
- 229960002751 imiquimod Drugs 0.000 description 1
- DOUYETYNHWVLEO-UHFFFAOYSA-N imiquimod Chemical compound C1=CC=CC2=C3N(CC(C)C)C=NC3=C(N)N=C21 DOUYETYNHWVLEO-UHFFFAOYSA-N 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 230000001024 immunotherapeutic effect Effects 0.000 description 1
- 230000006057 immunotolerant effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 244000145841 kine Species 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 210000005210 lymphoid organ Anatomy 0.000 description 1
- 210000003563 lymphoid tissue Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- PIRWNASAJNPKHT-SHZATDIYSA-N pamp Chemical group C([C@@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)N)C(C)C)C1=CC=CC=C1 PIRWNASAJNPKHT-SHZATDIYSA-N 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 206010035485 plasmacytosis Diseases 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- 230000034190 positive regulation of NF-kappaB transcription factor activity Effects 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000013183 regulation of T cell differentiation Effects 0.000 description 1
- 230000012121 regulation of immune response Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 229940079827 sodium hydrogen sulfite Drugs 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 229940001482 sodium sulfite Drugs 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 239000006211 transdermal dosage form Substances 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
- C12N5/064—Immunosuppressive dendritic cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/26—Flt-3 ligand (CD135L, flk-2 ligand)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/998—Proteins not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/999—Small molecules not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
- C12N2502/1114—T cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/11—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells
Definitions
- the present invention relates to a method for producing immune tolerant plasmacytoid dendritic cells, an immune tolerant plasmacytoid dendritic cell produced by the method and a cell therapeutic agent comprising the same.
- the immune response and immune tolerance response must be balanced and balanced.
- a hyperimmune response occurs, for example, rheumatoid arthritis, autoimmune diseases of type 1 diabetes and sepsis and irritable allergic diseases can occur, which greatly affects the survival and quality of life of a person.
- dendritic cells were thought to act as an important axis only in inducing an immune response, but recently it is known that a significant contribution to the immune tolerance response has been actively studied.
- Dendritic cells play a pivotal role in regulating acquired immunity, which is selectively generated by acquired causality, as well as innate immunity. Specifically, dendritic cells perform a function of presenting information of externally invaded antigens to T cells. It is a kind of representative antigen presenting cells.
- the dendritic cells are cells that serve as a bridge between innate and acquired immunity, and correspond to the only cells capable of priming naive T cells among immune cells. It exists in the shape of a twig in each tissue cell gap of several tissues, including lymphoid tissue.
- the dendritic cells are finally differentiated cells, which are present in less than 1% of the total immune cells in the body, but are cells capable of inducing the activity of lymphocytes more strongly than monocytes or macrophages, and are immature in origin in bone marrow. In one form, it can travel through the bloodstream to all organs in the body. This allows dendritic cells to collect antigens around each tissue and move to lymphoid organs to deliver antigens to T lymphocytes, which can play an important role in T cell activation.
- the dendritic cells have been used as immune vaccines or immunotherapeutic agents, and both the immune vaccines and immunotherapeutics are known to be safe without side effects, and their use is expanding for various diseases.
- the dendritic cells are composed of various subpopulations according to origin, phenotype and function.
- plasmacytoide dendritic cells pDC
- pDC plasmacytoide dendritic cells
- cDCs conventional dendritic cells
- the pDC expresses B220
- CD11c expresses low levels
- cDCs express high levels of CD11c and CD11b, but does not express B220.
- Both pDCs and cDCs are obtained by the process of maturation of immature dendritic cells so that they can act as effective stimulators of a harmonious immune response.
- pDCs are known to play an important role in the defense of viral infections by activating immune cells by releasing large amounts of type I IFNs when infected by DNA viruses or single-stranded RNA viruses.
- mDCs mature DCs
- studies on the differentiation or role of pDCs in the body are insignificant compared to other dendritic cells.
- the inventors of the present invention have treated toll-like receptor agonists (TLR agonists) in immature dendritic cells to initiate differentiation, or toll-like receptor agonists during the process of differentiation of immature dendritic cells.
- TLR agonists toll-like receptor agonists
- One object of the present invention is to provide a method for producing a large amount of immune tolerant plasmacytoid dendritic cells from immature dendritic cells.
- Another object of the present invention is to provide a plasmacytoid dendritic cell prepared by the above method, and consistently showing immune tolerance.
- the present invention comprises the step of treating toll-like receptor agonist to immature dendritic cells, a method for producing immune tolerant plasmacytoid dendritic cells (pDC) To provide.
- pDC plasmacytoid dendritic cells
- the present invention also provides immune tolerant plasmacytoid dendritic cells induced by treating toll-like receptor agonists with immature dendritic cells.
- the present invention also provides a cell therapeutic agent comprising the immune tolerant plasmacytoid dendritic cells.
- the present invention can induce high yield of plasmacytoid dendritic cells having immune tolerance from immature dendritic cells through a simple and easy process, thereby enabling a stable supply of large amounts of immune tolerant plasmacytoid dendritic cells.
- the immune tolerant plasmacytoid dendritic cells obtained as described above induces the expression of anti-inflammatory cytokines, inhibits the expression of inflammatory cytokines, and promotes differentiation into regulatory T cells. It is possible to effectively prevent or treat an overactive immune disease or an allergic disease.
- FIG. 1 is a diagram showing the design of a method for treating differentiation-inducing factor (Flt3L-containing media) and toll-like receptor agonists (TLR agonists) for immature dendritic cells according to an embodiment of the present invention.
- Flt3L-containing media differentiation-inducing factor
- TLR agonists toll-like receptor agonists
- FIG. 2 is a diagram showing the separation of differentiation-induced plasma cytokine dendritic cells (TLRs-pDC) after the treatment of toll-like receptor agonist (Pam3) in Example 1 according to an embodiment of the present invention.
- TLRs-pDC differentiation-induced plasma cytokine dendritic cells
- Pam3 toll-like receptor agonist
- FIG. 3 (a) is a diagram showing surface expression molecules specifically induced in differentiation-induced plasmacytoid dendritic cells after treatment of a toll-like receptor agonist (Pam3) according to an embodiment of the present invention in Example 1 .
- Pam3 toll-like receptor agonist
- Figure 3 (b) is a graph of the ratio of the number of immature dendritic cells in Example 1 compared to the number of differentiation-induced plasma cytokine dendritic cells after treatment of toll-like receptor agonist (Pam3) according to an embodiment of the present invention The figure shown.
- FIG. 4 shows cytokines in differentiation-induced plasmacytoid dendritic cells (TLRs-pDC) and common plasmacytoid dendritic cells (pDC) after treatment of toll-like receptor agonist (Pam3) in Example 2 according to one embodiment of the present invention. It is a graph showing the result of comparing the expression pattern of the kine (IFN- ⁇ , IFN- ⁇ , IL-12p70, IL-10).
- Figure 5 shows the expression patterns of cytokine IL-10 in differentiation-induced plasmacytoid dendritic cells and general plasmacytoid dendritic cells (non) after treatment of various toll-like receptor agonists according to an embodiment of the present invention in Example 3 Is a graph showing the results of comparing.
- FIG. 6 shows cytokines (IFN- ⁇ , IFN- ⁇ , TNF- ⁇ , IL) according to the time point of treatment of toll-like receptor agonist (Pam3) treated to immature dendritic cells according to an embodiment of the present invention in Example 4.
- -12p70, IL-10) is a graph showing the results of comparing the expression pattern.
- TLRs-pDC differentiation-induced plasmacytoid dendritic cells
- pDC general plasmacytoid dendritic cells
- a graph showing the results of comparing the expression patterns of the complex molecules, CD80 and CD86.
- FIG. 8 shows IDO in differentiation-induced plasmacytoid dendritic cells (TLRs-pDC) and common plasmacytoid dendritic cells (pDC) after treatment of toll-like receptor agonist (Pam3) in Example 6.
- TLRs-pDC differentiation-induced plasmacytoid dendritic cells
- pDC common plasmacytoid dendritic cells
- Pam3 toll-like receptor agonist
- TLRs-pDC plasmacytoid dendritic cells
- Pam3 toll-like receptor agonist
- FIG. 9 (b) shows the differentiation-induced differentiation of plasmacytoid dendritic cells (TLRs-pDC) or general plasmacytosis after treatment of toll-like receptor agonist (Pam3) according to one embodiment of the present invention. It is a graph showing the results of measuring the proliferation rate of regulatory T cells after the treatment of id dendritic cells (pDC).
- FIG. 10 is a diagram showing the degree of binding of Rv1411c protein of dendritic cells (TLR2-/-) isolated from wild-type dendritic cells (WT) and TLR2 knockout mice in Example 8.
- FIG. 10 is a diagram showing the degree of binding of Rv1411c protein of dendritic cells (TLR2-/-) isolated from wild-type dendritic cells (WT) and TLR2 knockout mice in Example 8.
- FIG. 11 shows differentiation-induced plasmacytoid dendritic cells (Rv1411c (Rv1411c) after treatment of a toll-like receptor agonist (Rv1411c protein (0.1 ⁇ g / ml, 0.5 ⁇ g / ml)) according to an embodiment of the present invention in Example 9.
- 0.1 ⁇ g / ml) -pDC, Rv1411c (0.5 ⁇ g / ml) -pDC) and cytokine (IFN- ⁇ , IFN- ⁇ , TNF- ⁇ , IL-12p70, IL-) in common plasma cytokine dendritic cells (pDC) 10 is a graph showing the results of comparing the expression patterns of 10).
- Example 10 shows in Example 10 differentiation-induced plasmacytoid dendritic cells (Rv1411c-pDC) and general plasmacytoid dendritic cells (pDC) after treatment of toll-like receptor agonists (Rv1411c protein) according to one embodiment of the present invention.
- a graph showing the results of comparing the expression patterns of the MHC complex molecule, CD80, CD86 and immune tolerance induction molecules (IDO, CCR9 and PD-L1).
- Figure 13 shows the differentiation-induced plasmacytoid dendritic cells (Rv1411c-pDC) or general plasmacytoid dendritic cells after treatment of T cells in Example 11 and toll-like receptor agonist (Rv1411c protein) according to one embodiment of the present invention.
- pDC is a graph showing the results of comparing the degree of proliferation of T cells after the mixed culture.
- Figure 14 shows the differentiation-induced plasmacytoid dendritic cells (Rv1411c-pDC) or common plasmacytoid dendritic cells after treatment of T cells in Example 11 and toll-like receptor agonist (Rv1411c protein) according to one embodiment of the present invention.
- pDC is a graph showing the results of confirming the secretion pattern of IFN-gamma after the mixed culture.
- FIG. 15 (a) shows differentiation-induced plasmacytoid dendritic cells (Rv1411c-pDC) or general plasma after treatment of toll-like receptor agonist (Rv1411c protein) according to an embodiment of the present invention with respect to T cells in Example 12.
- cytokine dendritic cells (pDC) treatment is a diagram showing the results confirmed by the flow cytometry LSRFortessa x-20 proliferation to regulatory T cells.
- FIG. 15B shows differentiation-induced plasmacytoid dendritic cells (RVc1411c-pDC) or general plasma after treatment of Toll-like receptor agonist (Rv1411c protein) according to an embodiment of the present invention with respect to T cells in Example 12. It is a graph showing the results of measuring the proliferation rate of regulatory T cells after treating cytokine dendritic cells (pDC).
- FIG. 16 shows CD4 +, CD25- actuation of T cells differentiated by plasmacytoid dendritic cells (Rv1411c-pDC) induced after treatment of toll-like receptor agonist (Rv1411c protein) in Example 13;
- FIG. After incubating with T cells the graph shows the results of measuring the change in T cell proliferative capacity with respect to the ratio of primed T cells to CD25-acting T cells.
- TLR agonist plasmacytoid dendritic cells
- RYv1411c protein and Pam3 plasmacytoid dendritic cells induced after untreated treatment in Example 14;
- the graph which shows the result of comparing the number of (Non).
- the present invention relates to a method for producing immune tolerant plasmacytoid dendritic cells, comprising treating toll-like receptor agonists with immature dendritic cells.
- DC dendritic cell
- MHC major histocompatibility complex
- mDC mature dendritic cells
- the term “immature dendritic cell” is found in the early stages of maturation of dendritic cells and does not express CD14, the surface phenotype of monocyte cells, and also does not include any of the co-stimulatory molecules CD40, CD54, CD80, CD86 and CD274. One is expressed at low levels compared to mature dendritic cells.
- the term “quasi-dendritic dendritic cell” is a dendritic cell that loses some of the properties of immature dendritic cells and has some characteristics of the phenotype of mature dendritic cells, and partially or incompletely matured morphological and phenotypic characteristics. Meaning dendritic cells.
- mature dendritic cell refers to a cell formed by maturation of immature dendritic cells.
- Mature dendritic cells have high expression of MHC class II, CD40, CD54, CD80, CD86, and CD274 as well as DC-LAMP, release anti-inflammatory cytokine, and primitive allogeneic in mixed lymphocyte reactions. Characterized by having the ability to produce increased production of allogeneic T cells and syngeneic T cells and / or increased production of dendritic cell cytokines.
- Mature dendritic cells typically express high levels of CCR7 and CXCR4.
- the dendritic cells to which the toll-like receptor agonist is treated are preferably immature dendritic cells that are not differentiated.
- the immature dendritic cells may include primitive dendritic cells, and may be isolated and obtained from mammalian bone marrow or the like.
- the immune tolerant dendritic cells induced by differentiation by treating toll-like receptor agonists to immature dendritic cells as described above may be immune tolerant plasmacytoid dendritic cells (pDC).
- pDC plasmacytoid dendritic cells
- plasmacytoid dendritic cells refers to a subset of dendritic cells, 1958, Lennert and Dr. Plasmacytoid T cells, first known by histological detection of plasma cell morphology in human lymph nodes, but not expressing B cell specific markers (Plasmacytoid T cells) After being known to express myeloid lineage antigen and MHC class II without expressing CD3, a common marker of T cells, it was named plasmacyytoid monocyte. After that, the ability to induce an allerogenic mixed lymphocyte reaction (MLR), which is inherent in dendritic cells, has been identified, which is again referred to as plasmacytoid dendritic cells, or simply referred to as 'pDC'. do.
- MLR mixed lymphocyte reaction
- the term “immune tolerance” refers to a state that suppresses an immune response as well as a state that does not exhibit an immune response to a specific antigen. Therefore, in the present invention, the "immune tolerant plasmacytoid dendritic cells” promote the secretion of anti-inflammatory cytokines such as IL-10, inhibit the secretion of inflammatory cytokines such as IL-12p70 and TNF- ⁇ , Indoleamine-2,3 dioxygenase (IDO) molecules, recently known as immune tolerance inducing molecules, and CCR9, a surface molecule of immune tolerance induction cells, are expressed at high levels. Induce differentiation of regulatory T cells and inhibit the activity of effector T cells.
- anti-inflammatory cytokines such as IL-10
- IDO Indoleamine-2,3 dioxygenase
- immune tolerant plasmacytoid dendritic cells can be stably and in large quantities prepared by treating the toll-like receptor agonist before or during differentiation of immature dendritic cells.
- the term “before the differentiation” may include a time point before the differentiation-inducing factor is treated in immature dendritic cells.
- the term 'differentiating' means a time point from the time of processing the factor for inducing differentiation to the immature dendritic cells until the differentiation is completed by the factor for inducing differentiation. Preferably, it may include a time within 7 days after the treatment from the time of processing the factor for inducing differentiation, but is not limited thereto.
- the toll-like receptor agonist is not particularly limited as long as it is treated only before or during the differentiation of immature dendritic cells as described above.
- the toll-like receptor agonist may be treated within 7 days (168 hours), 5 days (120 hours) or 3 days (72 hours) from the start of differentiation.
- the present invention is not limited thereto.
- the immature dendritic cells may be depleted by using a factor for inducing differentiation within 36 hours, preferably 24 hours, after the agent is treated. Differentiation can be initiated, but is not limited thereto.
- the toll-like receptor agonist may be treated one or more times, and the number of specific treatments is not particularly limited, but when the toll-like receptor agonist is treated during differentiation of immature dendritic cells, the immature dendritic cells are differentiated.
- the toll like receptor agonist may be treated at least once within 7, 5 or 3 days from the start.
- the immature dendritic cell is treated at least once with the toll-like receptor agonist, and then within 36 hours or 24 hours from any one treatment time point. Differentiation of immature dendritic cells may be initiated and optionally further treated one or more times during the differentiation.
- the "initiation of differentiation” may mean a process of adding a factor for inducing differentiation to a culture medium of immature dendritic cells or inoculating immature dendritic cells in a medium containing a factor for inducing differentiation.
- the differentiation-inducing factor is not particularly limited as long as it can induce differentiation of immature dendritic cells.
- the term "toll-like receptor agonist” is a pathogen-derived conserved molecular substance, which may be Pathogen associated molecular patterns (PAMPs).
- PAMPs Pathogen associated molecular patterns
- the pathogen may be Gram-positive bacterium, Gram-negative bacterium, fungus or virus.
- the toll-like receptor agonists are endogenous molecules released from damaged or dead cells, and may be Damage associated molecular patterns (DAMPs). DAMPs or PAMPs collect adapter molecules in the cytoplasm of the cell to initiate and transmit an immune response via the TLR signal.
- the toll like receptor agonist will be a derivative of PAMPs or DAMPs that bind to fragments, variants, analogs, homology or toll like receptors and induce activation by TLR-mediated, such as activation of NF- ⁇ B activity.
- TLR-mediated such as activation of NF- ⁇ B activity.
- the toll-like receptor agonist fragments, variants, analogs, homologs or derivatives are at least 30-99% identical to the amino acids of the TLR agonist and will induce activation by toll-like receptor-mediated.
- the type of toll-like receptor agonist to be treated to the immature dendritic cells is not particularly limited, but is preferably a PAMP ligand, more preferably immature that can pass through MyD88 (Myeloid differentiation primary response gene 88) signal. Differentiation of immune tolerant plasmacytoid dendritic cells can be induced from dendritic cells.
- the toll-like receptor agonist in the present invention may include one or more selected from the group consisting of TLR2 agonist, TLR4 agonist, TLR5 agonist, TLR7 agonist, TLR8 agonist, TLR9 agonist, TLR11 agonist, TLR12 agonist and TLR13 agonist.
- TLR2 agonist TLR4 agonist
- TLR5 agonist TLR5 agonist
- TLR7 agonist TLR8 agonist
- TLR9 agonist TLR11 agonist
- TLR12 agonist and TLR13 agonist TLR13 agonist.
- one or more of the ligands shown in Table 1 may be included, but is not particularly limited thereto, and may bind to toll-like receptors of dendritic cells, and may be a ligand that may pass through a MyD88 signal. Can be used without limitation.
- the TLR2 agonist when used as the toll-like receptor agonist in the present invention, it may further include at least one of a TLR1 agonist and a TLR6 agonist that acts as a co-receptor.
- a TLR1 agonist and a TLR6 agonist that acts as a co-receptor.
- specific examples of the TLR1 agonist and the TLR6 agonist may be ligands shown in Table 1 below, but any ligand that may act as a co-receptor of the TLR2 agonist is not particularly limited.
- the toll-like receptor agonist may be derived from a microorganism, a virus, a plant or an animal, may be synthesized, and the source is not particularly limited.
- the differentiation of the immature dendritic cells in the present invention can be performed using a factor for inducing differentiation.
- the factor for inducing differentiation it is preferable to use FMS-like tyrosine kinase 3 ligand (FMS-like tyrosine kinase 3, Flt3L).
- the immature dendritic cells may be plasmacytoid dendritic cells and general dendritic cells (conventional). There is no particular limitation as long as it can induce differentiation into plasmacytoid cells (cDCs).
- the differentiation of the immature dendritic cells in the present invention may be performed by culturing the immature dendritic cells in a medium containing a factor for inducing differentiation, or by adding the factor for inducing differentiation to the culture medium of the immature dendritic cells.
- the factor for inducing differentiation may be additionally added one or more times during the process of differentiating the immature dendritic cells.
- FMS-like tyrosine kinase 3 (Flt3L) corresponds to endogenous small molecules that activate hematopoietic progenitors to perform cytokines and growth factors. do.
- the differentiation period of the immature dendritic cells in the present invention is not particularly limited, and may vary depending on the type and environment of the medium used, for example, may be performed for 5 to 15 days, preferably 7 days May be carried out for 10 to 10 days, more preferably for 8 to 9 days.
- the immune tolerance of the plasmacytoid dendritic cells can be activated.
- the kind of toll-like receptors used for activating the differentiated immune tolerant plasmacytoid dendritic cells as described above is not particularly limited. It may include one or more selected from the group consisting of, TLR7 agonist, TLR8 agonist, TLR9 agonist, TLR11 agonist, TLR12 agonist and TLR13 agonist, but preferably TLR9 agonist may be used.
- the above-described process can effectively induce differentiation from immature dendritic cells to immune tolerant plasmacytoid dendritic cells. Accordingly, immature dendritic cells can be used to stably supply a large amount of immune tolerant plasmacytoid dendritic cells through a simple and easy process.
- the present invention relates to an immune tolerant plasmacytoid dendritic cell prepared by the above method.
- the immune tolerant plasmacytoid dendritic cells obtained in the present invention can induce differentiation of regulatory T cells and inhibit the activity of effector T cells to effectively suppress the immune response.
- the present invention also relates to a cell therapeutic agent comprising the immune tolerant plasmacytoid dendritic cells.
- cell therapeutic agent refers to the proliferation, screening, or other methods of biological characteristics of cells in vitro for autologous, allogenic, xenogenic cells to restore the function of cells and tissues.
- These cell therapies can be broadly classified into two categories, the first of which is an immune cell therapy for the regulation of immune responses, such as the suppression of immune responses or the enhancement of immune responses, and the second is a stem for tissue regeneration or long-term function recovery.
- Cell therapy the cell therapy provided by the present invention may be the immune cell therapy.
- the cell therapeutic agent may be used to induce differentiation or promote the activity of regulatory T cells, and particularly to prevent or treat autoimmune diseases, irritable immune diseases and various allergic diseases by effectively suppressing the immune response.
- the route of administration of the cell therapeutic agent may be administered through any general route as long as it can reach the target tissue.
- Parenteral administration for example, intraperitoneal administration, intravenous administration, intramuscular administration, subcutaneous administration, intradermal administration may be, but is not limited thereto.
- the composition may be formulated in a suitable form with a pharmaceutical carrier generally used for cell therapy.
- 'Pharmaceutically acceptable' refers to a composition that is physiologically acceptable and does not normally cause an allergic or similar reaction, such as gastrointestinal disorders, dizziness, etc. when administered to a human.
- Pharmaceutically acceptable carriers include, for example, water, suitable oils, saline, carriers for parenteral administration such as aqueous glucose and glycols, and the like, and may further include stabilizers and preservatives.
- Suitable stabilizers include antioxidants such as sodium hydrogen sulfite, sodium sulfite or ascorbic acid.
- Suitable preservatives include benzalkonium chloride, methyl- or propyl-paraben and chlorobutanol.
- the cell therapeutic agent may be administered by any device capable of moving to a target cell.
- the cell therapy agent of the present invention may include a therapeutically effective amount of cell therapy agent for the treatment of a disease.
- a therapeutically effective amount means the amount of an active ingredient or pharmaceutical composition that induces a biological or medical response in a tissue system, animal or human, as thought by a researcher, veterinarian, doctor or other clinician. Amounts that induce alleviation of the symptoms of the disease or disorder being treated. It is apparent to those skilled in the art that the content (number) of plasma cytokine dendritic cells included in the cell therapeutic agent of the present invention will vary depending on the desired effect.
- the optimal cell therapeutic content can be readily determined by one skilled in the art and includes the type of disease, the severity of the disease, the amount of other components contained in the composition, the type of formulation, and the age, weight, general health, sex and diet of the patient. It can be adjusted according to various factors including the administration time, the route of administration and the rate of administration of the composition, the duration of treatment, the drug used concurrently, for example, 2x10 4 cells / ml ⁇ 8x10 7 cells / ml plasmacytoid dendritic Cells may be included, but are not limited thereto.
- the composition comprising the cell therapeutic agent of the present invention as an active ingredient is conventionally used through rectal, intravenous, arterial, intraperitoneal, intramuscular, intrasternal, transdermal, topical, intraocular subcutaneous or intradermal routes. It may be administered in a phosphorous manner.
- the cell therapeutic agent comprising the immune tolerant plasmacytoid dendritic cells of the present invention as an active ingredient may be used as an external preparation for skin for the prevention or improvement of autoimmune diseases, irritable immune diseases or allergic diseases.
- the formulation is not particularly limited. Specifically, for example, it may be a cosmetic composition having a formulation of a softening lotion, nourishing lotion, massage cream, nutrition cream, pack, gel or skin adhesive type cosmetics, and may also be a lotion, ointment, gel, cream, patch or spray Transdermal dosage forms.
- femoral bone marrow was collected from bone marrow harvesting injections from C57BL / 6 mice.
- the collected bone marrow was washed with phosphate buffer saline (PBS) and red blood cells were removed using ammonium chloride.
- PBS phosphate buffer saline
- the isolated cells (3 ⁇ 10 6 cells / well) were seeded in 6-well plates, followed by 10% FBS (Fetal bovine serum, calf serum), 2 mM L-glutamine, 100 U / ml penicillin / streptomycin, 50 ⁇ M.
- Incubation and differentiation were initiated by addition of 1 ml RPMI 1640 comprising mercaptoethanol, 0.1 mM non-essential amino acid, 1 mM sodium pyruvate and 250 ng / ml FLT3L.
- Pam 3 was treated at a concentration of 100-500 ng / ml.
- 1 ml of RPMI 1640 was supplemented and incubated for 8 days.
- the cells obtained after the cultivation were subjected to plasmacytoid dendritic cells using a plasmacytoid dendritic cell separation kit (Miltenyi Biotec, Auburn, CA) and a magnetic cell sorting system (Vario MACS: Miltenyi Biotec, Auburn, CA). Separation (FIG. 2). Since the treatment of the toll-like receptor agonist may affect the differentiation of the plasmacytoid dendritic cells, the surface-expressing molecules specifically induced in the plasmacytoid dendritic cells are confirmed on the 8th day, and the results are shown in FIG. ).
- a plasmacytoid dendritic cell separation kit Miltenyi Biotec, Auburn, CA
- Vario MACS Miltenyi Biotec, Auburn, CA
- the toll-like receptor agonist when the toll-like receptor agonist was treated (TLRs-pDC), the ratio of the number of plasmacytoid dendritic cells obtained after 8 days to the number of initial immature dendritic cells was measured, and the result is shown in FIG. ).
- the case where the toll-like receptor agonist was not treated is shown as a comparative example (pDC).
- Example 2 In order to confirm the cytokine secretion of the plasma cytokine dendritic cells isolated in Example 1, inoculated cells (5 ⁇ 10 5 cells / ml) in 48 well plate and then ODN1826 (1 ⁇ g / ml) Treatment was stimulated. After 24 hours, the obtained supernatant was separated, and cytokine secretion was confirmed by an enzyme-linked immunosorbent assay (ELISA). The results are shown in FIG. 4. However, in order to confirm the treatment effect of the toll-like receptor agonist, the case where the toll-like receptor agonist was not treated during differentiation of immature dendritic cells in Example 1 is shown as a comparative example (pDC).
- pDC comparative example
- plasma-cytoid dendritic cells strongly induced type I interferons (IFN- ⁇ and IFN- ⁇ ) and representative inflammatory cytokines TNF- ⁇ and IL-12p70.
- toll-like receptor agonists 0.5 ⁇ g / ml
- TLRs-pDC differentiation-induced plasmacytoid dendritic cells
- ODN1826 ODN1826.
- IL-10 an immunosuppressive cytokine
- plasmacytoid dendritic cells induced by differentiation by treating a toll-like receptor agonist to immature dendritic cells according to the present invention were found to have immune tolerance unlike conventional plasmacytoid dendritic cells.
- plasmacytoid dendritic cells were induced in the same manner as in Example 1, but as the toll-like receptor agonist, ligands shown in Table 2 were used. After 8 days of incubation, plasmacytoid dendritic cells were separated with a purity of 85% or more using a plasmacytoid dendritic cell separation kit (Miltenyi Biotec, Auburn, CA) and a magnetic cell sorting system (Vario MACS: Miltenyi Biotec, Auburn, CA). It was.
- a plasmacytoid dendritic cell separation kit Miltenyi Biotec, Auburn, CA
- Vario MACS Miltenyi Biotec, Auburn, CA
- Isolated cells (5 ⁇ 10 5 cells / ml) were inoculated in 48 well plates, treated with ODN1826 (1 ⁇ g / ml) and incubated for 24 hours. Thereafter, only the supernatant was separated and the secretion pattern of the immunosuppressive cytokine IL-10 was confirmed by enzyme immunoassay. The results are shown in FIG. 5. However, in order to confirm the treatment effect of the toll-like receptor agonist, the case where the toll-like receptor agonist was not treated during differentiation of immature dendritic cells is shown as a comparative example (non).
- the differentiation of plasmacytoid dendritic cells is induced in the same manner as in Example 1, but the time to start the differentiation of the toll-like receptor agonist (0 day treatment)
- the treatment was performed after 3 days from the start of differentiation (3 day treatment).
- the plasmacytoid dendritic cells were purified to 85% or higher using a plasmacytoid dendritic cell separation kit (Miltenyi Biotec, Auburn, CA) and a magnetic cell sorting system (Vario MACS: Miltenyi Biotec, Auburn, CA). Separated.
- Isolated cells (5 ⁇ 10 5 cells / ml) were inoculated in 48 well plates, treated with ODN1826 (1 ⁇ g / ml) and incubated for 24 hours. After separating only the supernatant, the secretion pattern of cytokines was confirmed by enzyme immunoassay, and the results are shown in FIG. 6. However, in order to confirm the treatment effect of the toll-like receptor agonist, the case where the toll-like receptor agonist was not treated during the differentiation of immature dendritic cells is shown as a comparative example (no-treatment, non).
- the toll-like receptor agonist is treated at the start of differentiation of immature dendritic cells, that is, at the same time as FLT3L, a factor for inducing differentiation, the differentiation of immune tolerant plasmacytoid dendritic cells is induced as in the case of differentiation. there was.
- Dendritic cells including plasmacytoid dendritic cells, present antigens through MHC molecules to activate T cells upon recognition of foreign antigens and express co-stimulatory factors such as CD80 and CD86 to facilitate interaction.
- the plasmacytoid dendritic cells isolated in Example 1 were stimulated with ODN1826 and then cultured for 24 hours to confirm the expression level of the cell surface molecules.
- specific markers of plasmacytoid dendritic cells anti-CD11c (PE-Cy7, BD Biosciences), anti-PDCA-1 (PerCP-eFluor® 710 , ebioscience) and anti-CD80 (v450, BD Biosciences), anti-CD86 (APC, ebioscience), anti-MHC-I (PE, ebioscience) and anti-MHC-II (APC-eFluor) specific for cell surface molecules 780, ebioscience)
- the antibody was treated for 30 minutes at 4 ° C and analyzed by flow cytometry LSRFortessa x-20 (BD Biosciences). The results are shown in FIG. However, in order to confirm the treatment effect of the toll-like receptor agonist
- pDCs general plasmacytoid dendritic cells express high levels of co-stimulating factor CD86 and MHC class II molecules exogenous antigen presentation, but differentiation-induced plasma by treating toll-like receptor agonists Cytoid dendritic cells (TLRs-pDC) showed no or no response. Meanwhile, another co-stimulatory factor, CD80, and MHC class I molecules presenting endogenous or cross-antigens, were treated with toll-like receptor agonists and were not treated with differentiation-induced plasmacytoid dendritic cells (TLRs-pDC). It was confirmed that the expression at a higher level than (pDC).
- anti-CD11c PE-Cy7, BD Biosciences
- markers specific for plasmacytoid dendritic cells and Cell surface factor antibodies such as anti-PDCA-1 (PerCP-eFluor® 710, ebioscience) and immune tolerance induced cell surface molecules, such as anti-PD-L1 (PE, ebioscience) and anti-CCR9 (FITC, ebioscience)
- anti-PDCA-1 PerCP-eFluor® 710, ebioscience
- immune tolerance induced cell surface molecules such as anti-PD-L1 (PE, ebioscience) and anti-CCR9 (FITC, ebioscience
- CCR9 and IDO molecules were significantly increased compared to the untreated plasmacytoid dendritic cells upon stimulation with ODN1826.
- the expression of CCR9 was higher than that of untreated plasmacytoid dendritic cells even when unstimulated.
- TLRs-pDC differentiation-induced plasma cytokine dendritic cells
- RPMI1640 culture medium containing 10% FBS, 1% antibiotic and 100ng / ml of granulocyte-macrophage-colony stimulating factor (GM-CSF) was used for differentiation of dendritic cells. Incubated for 8 days. After 8 days of incubation, 5 ⁇ g / ml of Rv1411c protein was treated to wild-type dendritic cells (WT) and TLR2 knockout mice (TLR2-/-), respectively, and mixed for 2 hours intermittently. Facilitated. Then, the Hisv labeled with the Rv1411c protein was stained with an antibody having antigen-antibody specificity, and the degree of binding was measured using a flow cytometer. The results are shown in FIG. 10.
- wild-type dendritic cells showed increased binding to Rv1411c protein compared to TLR2 knockout dendritic cells (TLR2-/-), but in TLR2 knockout dendritic cells (TLR2-/-). Although the Rv1411c protein was treated, the same degree of binding as the untreated experimental group was confirmed.
- Rv1411c protein binds to the TLR2 receptor and has activity as a TL2 agonist.
- Example 8 Induced differentiation of immune tolerant plasmacytoid dendritic cells in the same process as in Example 1, but as the toll-like receptor agonist, the Rv1411c protein (0.1 ⁇ g / ml) was confirmed as a toll-like receptor agonist in Example 8. , 0.5 ⁇ g / ml) was used. After 8 days of incubation, plasmacytoid dendritic cells were separated with a purity of 85% or more using a plasmacytoid dendritic cell separation kit (Miltenyi Biotec, Auburn, CA) and a magnetic cell sorting system (Vario MACS: Miltenyi Biotec, Auburn, CA). It was.
- a plasmacytoid dendritic cell separation kit Miltenyi Biotec, Auburn, CA
- Isolated cells (5 ⁇ 10 5 cells / ml) were seeded in 48 well plates, treated with ODN1826 (1 ⁇ g / ml) and incubated for 24 hours. The supernatant obtained after the cultivation was isolated, and the results of confirming cytokine secretion by Enzyme Linked Immunosorbent assay (ELISA) are shown in a graph of FIG. 11. However, in order to confirm the treatment effect of Rv1411c protein, Rv1411c protein was untreated, and typical plasma cytoid dendritic cells stimulated (ODN +) or unstimulated (ODN ⁇ ) with ODN1826 are shown as comparative examples (pDC).
- ODN1826 Enzyme Linked Immunosorbent assay
- Rv1411c As shown in FIG. 11, stimulation of plasmacytoid dendritic cells (Rv1411c (0.1 ⁇ g / ml) -pDC, Rv1411c (0.5 ⁇ g / ml) -pDC) treated with Rv1411c protein with ODN1826 results in normal plasmacytoid dendritic cells.
- the concentrations of strongly induced type I interferons (IFN- ⁇ and IFN- ⁇ ) and the representative inflammatory cytokines TNF- ⁇ and IL-12p70 were rapidly reduced in a dose-dependent manner.
- IL-10 was found to increase its expression level in a concentration dependent manner.
- the plasmacytoid dendritic cells treated with the Rv1411c protein have immune tolerance differently from the ordinary plasmacytoid dendritic cells, and the degree of immune tolerance also increases in proportion to the concentration of the Rv1411c protein.
- Example 9 the expression patterns of surface molecules and enzymes in the plasmacytoid dendritic cells induced differentiation with Rv1411c protein were confirmed.
- the markers specific for plasmacytoid dendritic cells were treated at 4 ° C.
- anti-CD11c PE-Cy7, BD Biosciences
- anti-PDCA-1 PerCP-eFluor 710, ebioscience
- Anti-CD80 v450, BD Biosciences
- anti-CD86 APC, ebioscience
- anti-MHC-I PE, ebioscience
- anti-MHC-II APC-eFluor® 780, ebioscience
- anti-PD Cell surface factor antibodies such as -L1 (PE, ebioscience) and anti-CCR9 (FITC, ebioscience) were treated at 4 ° C.
- the most important feature in vivo of immune tolerant plasmacytoid dendritic cells is to inhibit the activity of T lymphocytes.
- the following experiment was performed to determine the effect of differentiation-induced plasma cytokine dendritic cells on the proliferation and activity of T cells by treating Rv1411c protein in Example 9.
- T cells 1.5 ⁇ 10 5 cells / well isolated from allogeneic mice and stained with CellTrace (Invitrogen) were stimulated through 1 ⁇ PMA / Ionomycin (ebioscience). This treatment of PMA / Ionomycin increases the proliferation rate of T lymphocytes and promotes the secretion of interferon gamma (IFN-gamma).
- IFN-gamma interferon gamma
- the cells were treated with Tv and Rv1411c protein to induce differentiation-induced differentiation of plasmacytoid dendritic cells (Rv1411c-pDC) or general plasmacytoid dendritic cells (pDC) in a ratio of 1: 5 and incubated for 3 days. .
- Rv1411c protein was untreated, and typical plasma cytoid dendritic cells stimulated (ODN +) or unstimulated (ODN ⁇ ) with ODN1826 are shown as comparative examples (pDC).
- both plasmavoid dendritic cells (Rv1411c-pDC) and general plasmacytoid dendritic cells (pDC) induced by differentiation by treating Rv1411c protein induced T cell proliferation, but treated with Rv1411c protein to differentiate.
- the induced plasmacytoid dendritic cells (Rv1411c-pDC) were observed to have much lower proliferative induction capacity for CD4 + T cells than normal plasmacytoid dendritic cells (pDC).
- the secretion of IFN-gamma was lowered at a lower level than that of the non-treated plasmacytoid dendritic cells (pDCs) in which plasmavoid dendritic cells (Rv1411c-pDCs) induced by differentiation were treated with Rv1411c protein. I could see the induction.
- T cells stained with CellTrace (Invitrogen) after isolation from allogeneic mice were treated with Rv1411c protein in Example 9 to induce differentiation of plasmacytoid dendritic cells (Rv1411c-pDC) or normal plasmacytoid dendritic cells (pDC). The ratio was 10: 1, 5: 1, or 1: 1 and incubated for 5 days. However, as the plasmacytoid dendritic cells were used ODN1826 stimulated (ODN +) and unstimulated (ODN-). Five days after incubation, cells were treated with anti-CD4 (Percp-cy5.5, ebioscience) for 30 minutes at 4 ° C. and Foxp3 / transcription factor staining buffer (ebioscience) at 37 ° C.
- T cells are reported to induce immune tolerant dendritic cells and inhibit the proliferation of other T cells. Therefore, below, according to Example 12, the activity of T cells induced by differentiation by Rv1411c protein as regulatory T cells was confirmed.
- mice spleens are isolated, red blood cells are removed, and CD4 + and CD25- activated T cells are isolated using a magnetic cell sorting system (MACS), and then stained with a violet proliferation dye to determine the extent of proliferation. It was. Differentiated T cells were then incubated for two days in wells coated with anti-CD3e and anti-CD28 antibodies with CD4 +, CD25- effector T cells. As a result, the change in T cell proliferative capacity was measured with respect to the ratio of primed T cells to CD25-acting T cells, and is graphically shown in FIG. 16.
- MCS magnetic cell sorting system
- Toll-like receptor agonist was further treated in the differentiation-induced immune tolerant plasmacytoid cells according to the present invention, it effectively inhibits the activity of effector T cells by activating immune tolerance.
- Femoral bone marrow was harvested using bone marrow harvesting injections from C57BL / 6 mice. The collected bone marrow was washed with phosphate buffer saline (PBS) and red blood cells were removed using ammonium chloride. Isolated cells (5 ⁇ 10 5 cells / well) were seeded in 6-well plates, followed by 10% FBS (Fetal bovine serum, calf serum), 2 mM L-glutamine, 100 U / ml penicillin / streptomycin, 50 ⁇ M Incubation and differentiation were initiated by addition of 1 ml RPMI 1640 comprising mercaptoethanol, 0.1 mM non-essential amino acid, 1 mM sodium pyruvate and 250 ng / ml FLT3L.
- PBS phosphate buffer saline
- Rv1411c protein and Pam3 were treated with a toll like receptor agonist at a concentration of 100-500 ng / ml.
- 1 ml of RPMI 1640 was supplemented and incubated for 8 days.
- the cells obtained after the cultivation were subjected to plasmacytoid dendritic cells using a plasmacytoid dendritic cell separation kit (Miltenyi Biotec, Auburn, CA) and a magnetic cell sorting system (Vario MACS: Miltenyi Biotec, Auburn, CA). Separation.
- TLR agonist plasmacytoid dendritic cells
- TLR agonist toll-like receptor agonists during the differentiation of immature dendritic cells
- Non plasmacytoid dendritic cells induced differentiation
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
Non | TLR2 작용제 | TLR3 작용제 | TLR4 작용제 | TLR7 작용제 | TLR9 작용제 |
미처리 | Pam3 | Poly I:C | LPS | 이미퀴모드 | CpG-ODN |
Claims (20)
- 미성숙 수지상 세포에 톨 유사 수용체 작용제(toll-like receptor agonist)를 처리하는 단계를 포함하는, 면역 관용성 플라즈마사이토이드 수지상 세포(plasmacytoid dendritic cells, pDC)의 제조방법.
- 제1항에 있어서,상기 톨 유사 수용체 작용제는 상기 미성숙 수지상 세포의 분화 개시 이전 또는 분화 중에 처리되어, 상기 면역 관용성 플라즈마사이토이드 수지상 세포로의 분화를 유도하는, 면역 관용성 플라즈마사이토이드 수지상 세포의 제조방법.
- 제1항에 있어서,상기 톨 유사 수용체 작용제는 상기 미성숙 수지상 세포의 분화 개시 시점으로부터 분화 완료 이전에 처리되는, 면역 관용성 플라즈마사이토이드 수지상 세포의 제조방법.
- 제2항 또는 제3항에 있어서,상기 미성숙 수지상 세포의 분화는 분화 유도용 인자를 사용하여 수행되는, 면역 관용성 플라즈마사이토이드 수지상 세포의 제조방법.
- 제4항에 있어서,상기 분화 유도용 인자는 FMS-유사 티로신 키네이즈 3 리간드(FMS-like tyrosine kinase 3, Flt3L)인, 면역 관용성 플라즈마사이토이드 수지상 세포의 제조방법.
- 제4항에 있어서,상기 분화 유도용 인자는 상기 미성숙 수지상 세포에 1회 이상 처리되는, 면역 관용성 플라즈마사이토이드 수지상 세포의 제조방법.
- 제1항에 있어서,상기 톨 유사 수용체 작용제는 상기 분화 유도용 인자와 동시에 상기 미성숙 수지상 세포에 처리되는, 면역 관용성 플라즈마사이토이드 수지상 세포의 제조방법.
- 제1항에 있어서,상기 톨 유사 수용체 작용제는 1회 이상 처리되는, 면역 관용성 플라즈마사이토이드 수지상 세포의 제조방법.
- 제1항에 있어서,상기 톨 유사 수용체 작용제는 MyD88(Myeloid differentiation primary response gene 88) 시그널을 경유하는 것인, 면역 관용성 플라즈마사이토이드 수지상 세포의 제조방법.
- 제1항에 있어서,상기 톨 유사 수용체 작용제는 TLR2 작용제, TLR4 작용제, TLR5 작용제, TLR7 작용제, TLR8 작용제, TLR9 작용제, TLR11 작용제, TLR12 작용제 및 TLR13 작용제로 이루어진 군에서 선택된 1종 이상을 포함하는, 면역 관용성 플라즈마사이토이드 수지상 세포의 제조방법.
- 제10항에 있어서,상기 톨 유사 수용체 작용제는 TLR1 작용제 및 TLR6 작용제 중 적어도 하나를 추가로 더 포함하는, 면역 관용성 플라즈마사이토이드 수지상 세포의 제조방법.
- 제2항에 있어서,상기 분화 유도된 면역 관용성 플라즈마사이토이드 수지상 세포에 톨 유사 수용체 작용제를 추가로 처리하여 면역 관용성을 활성화시키는 단계를 더 포함하는, 면역 관용성 플라즈마사이토이드 수지상 세포의 제조방법.
- 제12항에 있어서,상기 면역 관용성을 활성화시키기 위하여 사용되는 상기 톨 유사 수용체 작용제는 TLR9 작용제인, 면역 관용성 플라즈마사이토이드 수지상 세포의 제조방법.
- 미성숙 수지상 세포에 톨 유사 수용체 작용제를 처리하여 유도된 면역 관용성 플라즈마사이토이드 수지상 세포.
- 제14항에 있어서,상기 면역 관용성 플라즈마사이토이드 수지상 세포는, 상기 미성숙 수지상 세포의 분화 개시 이전 또는 분화 중에 상기 톨 유사 수용체 작용제가 처리되어 분화 유도된 것인, 면역 관용성 플라즈마사이토이드 수지상 세포.
- 제14항에 있어서,상기 톨 유사 수용체 작용제는 TLR2 작용제, TLR4 작용제, TLR5 작용제, TLR7 작용제, TLR8 작용제, TLR9 작용제, TLR11 작용제, TLR12 작용제 및 TLR13 작용제로 이루어진 군에서 선택된 1종 이상을 포함하는, 면역 관용성 플라즈마사이토이드 수지상 세포.
- 제16항에 있어서,상기 톨 유사 수용체 작용제는 TLR1 작용제 및 TLR6 작용제 중 적어도 하나를 추가로 더 포함하는, 면역 관용성 플라즈마사이토이드 수지상 세포.
- 제14항 내지 제17항 중 어느 한 항의 면역 관용성 플라즈마사이토이드 수지상 세포를 포함하는 세포 치료제.
- 제18항에 있어서,상기 세포 치료제는 조절 T 세포(regulatory T cells)로의 분화를 유도하는, 세포 치료제.
- 제18항에 있어서,상기 세포 치료제는 작동 T 세포(effector T cells)의 활성을 억제하는, 세포 치료제.
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2018215740A AU2018215740A1 (en) | 2017-01-31 | 2018-01-30 | Plasmacytoid dendritic cells having immune tolerance, and method for producing same |
US16/482,094 US20200190473A1 (en) | 2017-01-31 | 2018-01-30 | Plasmacytoid Dendritic Cells Having Immune Tolerance, and Method for Producing Same |
BR112019015785-9A BR112019015785A2 (pt) | 2017-01-31 | 2018-01-30 | Células dendríticas plasmocitóides tendo tolerância imune e método para a produção das mesmas |
EP18747649.4A EP3578642A4 (en) | 2017-01-31 | 2018-01-30 | PLASMA CYTOID DENDRITIC CELLS WITH IMMUNOL TOLERANCE AND METHOD FOR THE PRODUCTION THEREOF |
CA3052132A CA3052132A1 (en) | 2017-01-31 | 2018-01-30 | Plasmacytoid dendritic cells having immune tolerance, and method for producing same |
CN201880009575.6A CN110337491A (zh) | 2017-01-31 | 2018-01-30 | 免疫耐受性浆细胞样树突状细胞及其制备方法 |
JP2019541284A JP2020505050A (ja) | 2017-01-31 | 2018-01-30 | 免疫寛容性プラズマサイトイド樹状細胞及びその製造方法 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020170014018A KR101946572B1 (ko) | 2017-01-31 | 2017-01-31 | 면역 관용성 플라즈마사이토이드 수지상 세포 및 그 제조방법 |
KR10-2017-0014018 | 2017-01-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2018143652A1 true WO2018143652A1 (ko) | 2018-08-09 |
Family
ID=63040862
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2018/001299 WO2018143652A1 (ko) | 2017-01-31 | 2018-01-30 | 면역 관용성 플라즈마사이토이드 수지상 세포 및 그 제조방법 |
Country Status (9)
Country | Link |
---|---|
US (1) | US20200190473A1 (ko) |
EP (1) | EP3578642A4 (ko) |
JP (1) | JP2020505050A (ko) |
KR (1) | KR101946572B1 (ko) |
CN (1) | CN110337491A (ko) |
AU (1) | AU2018215740A1 (ko) |
BR (1) | BR112019015785A2 (ko) |
CA (1) | CA3052132A1 (ko) |
WO (1) | WO2018143652A1 (ko) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB202014920D0 (en) * | 2020-09-22 | 2020-11-04 | Unikum Therapeutics Aps | Methods for treating cancer and autoimmune and inflammatory diseases |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090131512A1 (en) * | 2007-10-31 | 2009-05-21 | Dynavax Technologies Corp. | Inhibition of type I in IFN production |
US9370558B2 (en) * | 2008-02-13 | 2016-06-21 | President And Fellows Of Harvard College | Controlled delivery of TLR agonists in structural polymeric devices |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005501550A (ja) * | 2001-08-30 | 2005-01-20 | スリーエム イノベイティブ プロパティズ カンパニー | 免疫反応調整剤分子を用いた形質細胞様樹状細胞を成熟させる方法 |
PT1651755E (pt) * | 2003-08-04 | 2011-01-18 | Imba Inst Molekulare Biotech | Método para imunoterapia de tumores |
EP1806395A1 (en) * | 2006-01-06 | 2007-07-11 | Stichting Sanquin Bloedvoorziening | Maturation of dendritic cells |
EP1840206A1 (en) * | 2006-03-28 | 2007-10-03 | Gsf-Forschungszentrum Für Umwelt Und Gesundheit, Gmbh | Compositions for the preparation of mature dendritic cells |
US8889124B2 (en) * | 2008-09-25 | 2014-11-18 | The Board Of Trustees Of The Leland Stanford Junior University | Tolerogenic populations of dendritic cells |
WO2010049152A1 (en) * | 2008-10-29 | 2010-05-06 | Helmholtz Zentrum München Deutsches Forschungszentrum Für Gesundheit Und Umwelt (Gmbh) | Novel composition for the preparation of mature dendritic cells |
WO2011023824A2 (en) * | 2009-08-31 | 2011-03-03 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Estrogen receptor modulators for the treatment of diseases involving plasmacytoid dendritic cells |
EA201290876A1 (ru) * | 2010-03-05 | 2013-03-29 | Президент Энд Феллоуз Оф Гарвард Колледж | Композиции индуцированных дендритных клеток и их использование |
KR101221590B1 (ko) * | 2010-10-11 | 2013-01-17 | 부산대학교 산학협력단 | 결핵균의 rv0351 단백질을 포함하는 수지상 세포의 성숙화 촉진용 조성물 |
CA2861107A1 (en) * | 2012-01-13 | 2013-07-18 | President And Fellows Of Harvard College | Controlled delivery of tlr agonists in structural polymeric devices |
-
2017
- 2017-01-31 KR KR1020170014018A patent/KR101946572B1/ko active IP Right Grant
-
2018
- 2018-01-30 CN CN201880009575.6A patent/CN110337491A/zh active Pending
- 2018-01-30 JP JP2019541284A patent/JP2020505050A/ja active Pending
- 2018-01-30 AU AU2018215740A patent/AU2018215740A1/en not_active Abandoned
- 2018-01-30 US US16/482,094 patent/US20200190473A1/en not_active Abandoned
- 2018-01-30 WO PCT/KR2018/001299 patent/WO2018143652A1/ko unknown
- 2018-01-30 BR BR112019015785-9A patent/BR112019015785A2/pt not_active IP Right Cessation
- 2018-01-30 EP EP18747649.4A patent/EP3578642A4/en not_active Withdrawn
- 2018-01-30 CA CA3052132A patent/CA3052132A1/en not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090131512A1 (en) * | 2007-10-31 | 2009-05-21 | Dynavax Technologies Corp. | Inhibition of type I in IFN production |
US9370558B2 (en) * | 2008-02-13 | 2016-06-21 | President And Fellows Of Harvard College | Controlled delivery of TLR agonists in structural polymeric devices |
Non-Patent Citations (4)
Title |
---|
BJORCK, PIA: "Plasmacytoid dendritic cell dichotomy: identification of IFN- a producing cells as a phenotypically and functionally distinct subset", THE JOURNAL OF IMMUNOLOGY, vol. 186, 2011, pages 1477 - 1485, XP055531717 * |
LIU, KO-JIUNN: "Dendritic cell , toll-like receptor, and the immune system", JOURNAL OF CANCER MOLECULES, 2006, pages 213 - 215, XP008133133 * |
See also references of EP3578642A4 * |
SIOUD ET AL.: "TLR agonists induce the differentiation of human bone marrow CD 34+ progenitors into CDllc+ CD 80/86+ DC capable of inducing a Th1? type response", EUROPEAN JOURNAL OF IMMUNOLOGY, vol. 37, no. 10, 2007, pages 2834 - 2846, XP008141629 * |
Also Published As
Publication number | Publication date |
---|---|
AU2018215740A1 (en) | 2019-08-22 |
US20200190473A1 (en) | 2020-06-18 |
EP3578642A1 (en) | 2019-12-11 |
CA3052132A1 (en) | 2018-08-09 |
BR112019015785A2 (pt) | 2020-03-17 |
JP2020505050A (ja) | 2020-02-20 |
EP3578642A4 (en) | 2020-07-29 |
CN110337491A (zh) | 2019-10-15 |
KR101946572B1 (ko) | 2019-02-11 |
KR20180089195A (ko) | 2018-08-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2018097540A2 (ko) | 무혈청면역세포배양용 배지첨가키트, 상기 키트를 이용한 면역세포배양방법, 상기 키트 또는 배양방법에 의해 얻어진 무혈청면역세포배양액 및 상기 배양액을 포함하는 화장료조성물 | |
WO2016209021A1 (ko) | 자연살해세포의 증식 방법 및 자연살해세포 증식용 조성물 | |
WO2016048107A1 (ko) | 인터페론-감마 또는 인터류킨-1베타를 처리한 줄기세포 또는 그 배양물을 포함하는 면역질환 또는 염증질환의 예방 또는 치료용 약학조성물 | |
WO2017146538A1 (ko) | 조절 t 세포 매개성 질환의 예방 또는 치료용 약학적 조성물 | |
WO2016018053A1 (ko) | 수지상세포의 제조방법, 이에 의해 제조된 수지상세포 및 그 용도 | |
WO2018143652A1 (ko) | 면역 관용성 플라즈마사이토이드 수지상 세포 및 그 제조방법 | |
Li et al. | Cholecystokinin octapeptide significantly suppresses collagen-induced arthritis in mice by inhibiting Th17 polarization primed by dendritic cells | |
WO2019103436A9 (ko) | Nk 세포 배양용 조성물 및 이를 이용하여 nk 세포를 배양하는 방법 | |
WO2015199402A1 (ko) | 특정 유전자 발현이 증가된 수지상세포의 제조방법 및 이를 이용하여 제조된 수지상세포를 포함하는 자가면역질환 치료 또는 예방용 조성물 | |
WO2017069512A1 (ko) | 바이러스 항원 특이적인 t 세포의 유도 및 증식 방법 | |
EP0630257B1 (en) | Thymus-derived, immune-enhancing agent for therapeutic use in immunocompromised hosts | |
WO2012050269A1 (ko) | 결핵균의 rv0351 단백질을 포함하는 수지상 세포의 성숙화 촉진용 조성물 | |
WO2022108306A1 (ko) | 인터류킨-33을 처리하여 면역원성이 향상된 cd103+ fcgr3+ 수지상세포의 제조방법 및 상기 수지상세포를 포함하는 면역항암치료용 약학적 조성물 | |
WO2018143649A1 (ko) | 자가 면역 질환의 예방 또는 치료용 약학적 조성물 및 그 제조방법 | |
WO2018143650A1 (ko) | 과민성 면역 질환의 예방 또는 치료용 약학적 조성물 및 그 제조방법 | |
WO2022108165A1 (ko) | 역분화 줄기세포 유래 중간엽 줄기세포로부터 분리된 엑소좀의 제조방법 및 이의 용도 | |
WO2015023165A1 (ko) | 염증조절복합체 및 stat3 신호분자 차단을 통한 면역조절능 최적화된 안정화 중간엽줄기세포 | |
WO2015194710A1 (ko) | Stat3 억제제가 처리된 간엽줄기세포를 유효성분으로 포함하는 면역질환의 예방 또는 치료용 조성물 | |
WO2019212123A1 (ko) | 수지상세포의 이동능을 증가시키는 방법 및 이의 용도 | |
WO2022255759A1 (ko) | 기능강화 줄기세포 및 조절 t 세포를 포함하는 아토피 피부염 예방 또는 치료용 병용투여 조성물 | |
KR101944723B1 (ko) | I형 인터페론을 이용한 골수유래 면역반응 억제세포의 제조방법, 이에 의해 제조된 골수유래 면역반응 억제세포 및 그 용도 | |
KR102003958B1 (ko) | 과민성 면역 질환의 예방 또는 치료용 약학적 조성물 및 그 제조방법 | |
WO2019066571A2 (ko) | 골수유래 면역반응 억제세포의 제조방법, 이에 의해 제조된 골수유래 면역반응 억제세포 및 그 용도 | |
WO2023106894A1 (ko) | Mr1 제한적 panck t 세포 및 이의 제조방법 | |
WO2022235072A1 (ko) | 수지상 세포의 배양 방법 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 18747649 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 3052132 Country of ref document: CA Ref document number: 2019541284 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112019015785 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 2018215740 Country of ref document: AU Date of ref document: 20180130 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2018747649 Country of ref document: EP Effective date: 20190902 |
|
ENP | Entry into the national phase |
Ref document number: 112019015785 Country of ref document: BR Kind code of ref document: A2 Effective date: 20190731 |